Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 68 of 1,261
  1. US 12202845

    Ras inhibitors

    Revolution Medicines, Inc. Β· Granted Jan 21, 2025 Β· Expires Jan 16, 2045

    granted
  2. US 12202877

    T cell receptors with mage-B2 specificity and uses thereof

    The Board of Regents of the University of Texas System Β· Granted Jan 21, 2025 Β· Expires Jan 16, 2045

    granted
  3. US 12201683

    Methods for preventing dengue and hepatitis a

    Takeda Vaccines, Inc. Β· Granted Jan 21, 2025 Β· Expires Jan 16, 2045

    granted
  4. US 12201591

    Sustained release compositions of endoxifen

    ATOSSA THERAPEUTICS, INC. Β· Granted Jan 21, 2025 Β· Expires Jan 16, 2045

    granted
  5. US 12201617

    HDAC6 inhibitors for treatment of metabolic disease and HFpEF

    Tenaya Therapeutics, Inc. Β· Granted Jan 21, 2025 Β· Expires Jan 16, 2045

    granted
  6. US 12201699

    Compositions and methods for promoting homology directed repair

    Editas Medicine, Inc. Β· Granted Jan 21, 2025 Β· Expires Jan 16, 2045

    granted
  7. US 12202883

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jan 21, 2025 Β· Expires Jan 16, 2045

    granted
  8. US 12202880

    HLA engineering methods and compositions for treatment of autoimmunity

    The Regents of the University of Colorado Β· Granted Jan 21, 2025 Β· Expires Jan 16, 2045

    granted
  9. US 12201685

    Methods of modulating immune responses with cationic lipid vaccine compositions

    The United States of America as Represented by the Secretary of the Department of Health and Human Services Β· Granted Jan 21, 2025 Β· Expires Jan 16, 2045

    granted
  10. CN 119343336

    1, 4-bis-(2-hydroxy-benzyl)-1, 4, 7-triazacyclononane derivatives and similar compounds as ligands in iron (iii) complexes for use as MRI contrast agents

    BRACCO IMAGING SPA Β· Granted Jan 21, 2025 Β· Expires Jan 16, 2045

    granted
  11. US 12202902

    FLT3-specific chimeric antigen receptors and methods using same

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Jan 21, 2025 Β· Expires Jan 16, 2045

    granted
  12. US 12202895

    LILRB4 antibodies and uses thereof

    The Board of Regents of the University of Texas System Β· Granted Jan 21, 2025 Β· Expires Jan 16, 2045

    granted
  13. US 12202832

    Heterocyclic compounds having a calcium-sensing receptor antagonistic activity

    Takeda Pharmaceutical Company Limited Β· Granted Jan 21, 2025 Β· Expires Jan 16, 2045

    granted
  14. US 12201700

    Micro- and nano-device for cartilage injury detection and treatment

    The Board of Regents of the University of Texas System Β· Granted Jan 21, 2025 Β· Expires Jan 16, 2045

    granted
  15. US 12201639

    Aqueous oral pharmaceutical suspension compositions

    ReveraGen BioPharma, Inc. Β· Granted Jan 21, 2025 Β· Expires Jan 16, 2045

    granted
  16. US 12201596

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC Β· Granted Jan 21, 2025 Β· Expires Jan 16, 2045

    granted
  17. US 12201453

    Microneedle fabrication and device implantation

    The Regents of the University of California Β· Granted Jan 21, 2025 Β· Expires Jan 16, 2045

    granted
  18. CN 119325492

    Fluorescent probe targeting CA-IX

    BRACCO IMAGING SPA Β· Granted Jan 17, 2025 Β· Expires Jan 12, 2045

    granted
  19. US 12195558

    Targeted delivery system and methods of use therefor

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Β· Granted Jan 14, 2025 Β· Expires Jan 9, 2045

    granted
  20. US 12194049

    Composition for treating carbapenem antibiotic-resistant Acinetobacter baumannii infection

    GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD Β· Granted Jan 14, 2025 Β· Expires Jan 9, 2045

    granted
  21. US 12195620

    Controlled entrapment and release of molecular cargo

    The Regents of the University of California Β· Granted Jan 14, 2025 Β· Expires Jan 9, 2045

    granted
  22. US 12195773

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. Β· Granted Jan 14, 2025 Β· Expires Jan 9, 2045

    granted
  23. US 12195804

    Treatment of squamous cell carcinoma

    The Board of Regents of the University of Texas System Β· Granted Jan 14, 2025 Β· Expires Jan 9, 2045

    granted
  24. US 12195766

    Tumor-selective E1a and E1b mutants

    The Regents of the University of California Β· Granted Jan 14, 2025 Β· Expires Jan 9, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.